<p><em><strong>休会 2025 年股东年会</strong></em></p>
<p><em><strong>敦促尚未投票的股东尽快投票</strong></em></p>
<p>Xenetic Biosciences, Inc.（NASDAQ:XBIO）（&#34;Xenetic&#34;或&#34;公司&#34;）是一家专注于推进创新免疫肿瘤技术以应对难治性癌症的生物制药公司，今天宣布其 2025 年股东年会（&#34;年会&#34;）已召开并因缺乏所需法定人数而休会，未进行任何业务。</p>
<p>召开年会需要法定人数。在年会上，出席的可投票股份少于已发行股份的多数，无论是亲自出席还是通过代理。因此，年会没有法定人数，决定休会以便为公司董事会征集更多代理投票提供额外时间。年会将于 2026 年 1 月 8 日星期四东部时间上午 10:00 重新召开，并将继续以虚拟形式举行。</p>
<p>已经提交代理或投票的股东无需再次投票，因为之前提交的代理和投票在重新召开的年会上仍然有效，除非被正式撤回。确定有资格在重新召开的年会上投票的股东的记录日期仍为 2025 年 10 月 15 日。</p>
<p><strong>截至 2025 年 10 月 15 日记录日期的股东，尚未投票的，鼓励在线投票，网址为</strong> <strong>www.proxyvote.com</strong> <strong>或拨打电话 1-800-690-6903。请在 2026 年 1 月 7 日东部时间晚上 11:59 之前投票。</strong></p>
<p>如果您在经纪公司、银行、交易商或其他类似组织的账户中持有公司的普通股，您可能会面临更早的投票截止日期，您应仔细查看持有这些股份的组织发送的任何材料，以了解如何投票，以确保您的投票被计算在内。</p>
<p>公司的年会正式代理声明副本可在 www.proxyvote.com 和公司网站 www.xeneticbio.com 上供股东查阅。</p>
<p>截至 2025 年 10 月 15 日年会营业结束时的 Xenetic 股东或其法定代理人，可以通过访问 http://www.virtualshareholdermeeting.com/XBIO2025 参加重新召开的年会。</p>
<p><strong>股东提问</strong></p>
<p>如果您有任何问题或需要投票的帮助，请致电 Okapi Partners LLC，电话 877-629-6355。</p>
<p><strong>重要信息</strong></p>
<p>本新闻稿可能被视为关于将于 2026 年 1 月 8 日星期四重新召开的年会的征集材料。与年会相关，公司于 2025 年 10 月 31 日向证券交易委员会（&#34;SEC&#34;）提交了正式代理声明。在做出任何投票决定之前，公司敦促股东阅读代理声明及任何其他与 SEC 提交的相关文件，因为这些文件包含有关年会的重要信息。正式代理声明已于 2025 年 10 月 31 日左右发送或提供给有权在年会上投票的股东。对股东在年会上投票的提案没有进行任何更改。公司向 SEC 提交的正式代理声明及任何其他材料可在 SEC 网站 www.sec.gov 或公司网站 www.xeneticbio.com 免费获取。</p>
<p><strong>关于 Xenetic Biosciences</strong></p>
<p>Xenetic Biosciences, Inc.是一家专注于推进创新免疫肿瘤技术以应对难治性癌症的生物制药公司。公司的专有 DNase 技术旨在通过靶向中性粒细胞外陷阱（NETs）来改善现有治疗的效果，包括免疫疗法，这些 NETs 与癌症进展有关。Xenetic 目前专注于将其系统性 DNase 项目推进到临床，作为胰腺癌和局部晚期或转移性实体瘤的辅助治疗。</p>
<p>欲了解更多信息，请访问公司网站 www.xeneticbio.com，并在 X、LinkedIn 和 Facebook 上与我们联系。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明，我们意图使其符合 1995 年《私人证券诉讼改革法》的安全港条款。本新闻稿中除历史事实陈述外的所有声明可能构成联邦证券法意义上的前瞻性声明。这些声明可以通过诸如 “预计”、“计划”、“项目”、“将”、“可能”、“预期”、“相信”、“应该”、“意图”、“估计”、“保持”、“关注”、“信心”、“潜力”、“持续”、“保证” 等词语以及其他类似含义的词语来识别，包括但不限于，所有关于我们专注于推进创新免疫肿瘤技术以应对难治性癌症的声明，DNase 平台通过靶向与癌症进展相关的中性粒细胞外陷阱（NETs）来改善现有治疗（包括免疫疗法）的结果，以及我们专注于将系统性 DNase 项目推进到临床作为胰腺癌和局部晚期或转移性实体瘤的辅助治疗的声明。此处包含的任何前瞻性声明均基于当前预期，并受到多种风险和不确定性的影响。许多因素可能导致我们的实际活动、表现、成就或结果与前瞻性声明中预期的活动和结果存在重大差异。可能导致实际活动、表现、成就或结果与此类计划、估计或预期存在重大差异的重要因素包括但不限于：（1）由于我们的制造和合作协议而产生的意外成本、费用或支出；（2）由于 DNase 平台的许可而产生的意外成本、费用或支出；（3）在 DNase 平台许可后，公司预期财务表现的不确定性；（4）未能实现 DNase 或 PolyXen 技术的预期潜力；（5）公司获得资金和实施其商业战略的能力；（6）董事会及其特别独立委员会进行的战略审查过程的结果和时机的不确定性，包括董事会在评估过程中可能决定不采取战略替代方案的可能性，公司因市场、监管和其他因素而无法完成审查所提出的任何战略替代方案的可能性，审查过程对我们业务造成的潜在干扰，以及评估过程的公告、暂停或完成及其结果对公司股价的潜在不利影响，以及与战略交易完成对公司当前业务运营、预期商业战略和产品开发计划的潜在影响相关的风险和不确定性；以及（7）其他风险因素，详见公司不时向 SEC 提交的报告，包括其 10-K 表格的年度报告、10-Q 表格的定期季度报告、8-K 表格的当前报告及其他向 SEC 提交的文件。上述重要因素的清单并不排他。此外，前瞻性声明也可能受到一般市场因素、一般经济和商业条件的负面影响，包括公共健康问题的潜在不利影响，以及地缘政治事件（如乌克兰和中东的冲突）对经济活动、竞争产品开发、产品可用性、联邦和州法规及立法、新产品候选和适应症的监管流程、可能出现的制造问题、专利状况、诉讼和股东行动主义等因素的影响。本文中包含的前瞻性声明仅在声明作出之日有效，公司不承担更新前瞻性声明的任何义务，法律要求的除外。</p>
<p><strong>联系方式：</strong></p>
<p>JTC Team, LLC</p>
<p>Jenene Thomas</p>
<p>(908) 824-0775</p>
<p>xbio@jtcir.com</p>
<p><strong>来源：</strong> Xenetic Biosciences, Inc.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNjkxNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNjkxNg"/></p>

XBIO

<p>Xenetic Biosciences, Inc. 宣布由于缺乏法定人数，2025 年股东年会将延期。会议将于 2026 年 1 月 8 日以虚拟形式重新召开。尚未投票的股东被敦促在 2026 年 1 月 7 日之前进行投票。已经提交的代理和投票仍然有效，除非被撤回。投票资格的记录日期为 2025 年 10 月 15 日。公司强调阅读已向 SEC 提交的代理声明以获取重要信息</p>

<p><em><strong>Adjourns 2025 Annual Meeting of Stockholders</strong></em></p>
<div class="lb-trans"><p><em><strong>休会 2025 年股东年会</strong></em></p>
</div><p><em><strong>Urges Stockholders Who Have Not Voted To Get Votes In</strong></em></p>
<div class="lb-trans"><p><em><strong>敦促尚未投票的股东尽快投票</strong></em></p>
</div><p>Xenetic Biosciences, Inc. (NASDAQ:XBIO) (&#34;Xenetic&#34; or the &#34;Company&#34;), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its 2025 Annual Meeting of Stockholders (the &#34;Annual Meeting&#34;) was convened and adjourned without any business conducted due to lack of the required quorum.</p>
<div class="lb-trans"><p>Xenetic Biosciences, Inc.（NASDAQ:XBIO）（&#34;Xenetic&#34;或&#34;公司&#34;）是一家专注于推进创新免疫肿瘤技术以应对难治性癌症的生物制药公司，今天宣布其 2025 年股东年会（&#34;年会&#34;）已召开并因缺乏所需法定人数而休会，未进行任何业务。</p>
</div><p>A quorum is necessary to hold the Annual Meeting. There were fewer than a majority of the outstanding shares entitled to vote present, either in person or by proxy, at the Annual Meeting. The Annual Meeting therefore had no quorum and was adjourned to allow additional time to solicit additional proxies on behalf of the Company's board of directors. The Annual Meeting will reconvene at 10:00 a.m. Eastern Time on Thursday, January 8, 2026, and will continue to be held virtually.</p>
<div class="lb-trans"><p>召开年会需要法定人数。在年会上，出席的可投票股份少于已发行股份的多数，无论是亲自出席还是通过代理。因此，年会没有法定人数，决定休会以便为公司董事会征集更多代理投票提供额外时间。年会将于 2026 年 1 月 8 日星期四东部时间上午 10:00 重新召开，并将继续以虚拟形式举行。</p>
</div><p>Stockholders who have already submitted a proxy or voted do not need to vote again, as proxies and votes previously submitted in respect of the Annual Meeting will remain valid at the reconvened Annual Meeting unless properly revoked. The record date for determining stockholders eligible to vote at the reconvened Annual Meeting remains October 15, 2025.</p>
<div class="lb-trans"><p>已经提交代理或投票的股东无需再次投票，因为之前提交的代理和投票在重新召开的年会上仍然有效，除非被正式撤回。确定有资格在重新召开的年会上投票的股东的记录日期仍为 2025 年 10 月 15 日。</p>
</div><p><strong>Stockholders as of the October 15, 2025 record date who have not yet voted are encouraged to vote online at</strong> <strong>www.proxyvote.com</strong> <strong>or by telephone at 1-800-690-6903. Please vote by 11:59 p.m. Eastern Time on January 7, 2026.</strong></p>
<div class="lb-trans"><p><strong>截至 2025 年 10 月 15 日记录日期的股东，尚未投票的，鼓励在线投票，网址为</strong> <strong>www.proxyvote.com</strong> <strong>或拨打电话 1-800-690-6903。请在 2026 年 1 月 7 日东部时间晚上 11:59 之前投票。</strong></p>
</div><p>If you hold your shares of the Company's common stock in an account at a brokerage firm, bank, dealer or other similar organization, you may be subject to an earlier voting deadline and you should carefully review any materials received from the organization holding those shares regarding how to vote to ensure your vote is counted.</p>
<div class="lb-trans"><p>如果您在经纪公司、银行、交易商或其他类似组织的账户中持有公司的普通股，您可能会面临更早的投票截止日期，您应仔细查看持有这些股份的组织发送的任何材料，以了解如何投票，以确保您的投票被计算在内。</p>
</div><p>A copy of the Company's definitive proxy statement for the Annual Meeting is available to stockholders on www.proxyvote.com and on the Company's website at www.xeneticbio.com.</p>
<div class="lb-trans"><p>公司的年会正式代理声明副本可在 www.proxyvote.com 和公司网站 www.xeneticbio.com 上供股东查阅。</p>
</div><p>Xenetic stockholders as of the close of business on the October 15, 2025 record date for the Annual Meeting, or their legal proxy holders, will be able to attend the reconvened Annual Meeting by visiting http://www.virtualshareholdermeeting.com/XBIO2025.</p>
<div class="lb-trans"><p>截至 2025 年 10 月 15 日年会营业结束时的 Xenetic 股东或其法定代理人，可以通过访问 http://www.virtualshareholdermeeting.com/XBIO2025 参加重新召开的年会。</p>
</div><p><strong>Stockholder Questions</strong></p>
<div class="lb-trans"><p><strong>股东提问</strong></p>
</div><p>If you have any questions or require any assistance in voting your shares, please call Okapi Partners LLC at 877-629-6355.</p>
<div class="lb-trans"><p>如果您有任何问题或需要投票的帮助，请致电 Okapi Partners LLC，电话 877-629-6355。</p>
</div><p><strong>Important Information</strong></p>
<div class="lb-trans"><p><strong>重要信息</strong></p>
</div><p>This press release may be deemed to be solicitation material in respect of the Annual Meeting to be reconvened and held on Thursday, January 8, 2026. In connection with the Annual Meeting, the Company filed a definitive proxy statement with the Securities and Exchange Commission (&#34;SEC&#34;) on October 31, 2025. BEFORE MAKING ANY VOTING DECISION, THE COMPANY URGES ITS STOCKHOLDERS TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The definitive proxy statement was sent or made available to stockholders entitled to vote at the Annual Meeting on or about October 31, 2025. No changes have been made to the proposals to be voted on by stockholders at the Annual Meeting. A copy of the definitive proxy statement and any other materials filed by the company with the SEC can be obtained free of charge at the SEC's website at www.sec.gov or the company's website at www.xeneticbio.com.</p>
<div class="lb-trans"><p>本新闻稿可能被视为关于将于 2026 年 1 月 8 日星期四重新召开的年会的征集材料。与年会相关，公司于 2025 年 10 月 31 日向证券交易委员会（&#34;SEC&#34;）提交了正式代理声明。在做出任何投票决定之前，公司敦促股东阅读代理声明及任何其他与 SEC 提交的相关文件，因为这些文件包含有关年会的重要信息。正式代理声明已于 2025 年 10 月 31 日左右发送或提供给有权在年会上投票的股东。对股东在年会上投票的提案没有进行任何更改。公司向 SEC 提交的正式代理声明及任何其他材料可在 SEC 网站 www.sec.gov 或公司网站 www.xeneticbio.com 免费获取。</p>
</div><p><strong>About Xenetic Biosciences</strong></p>
<div class="lb-trans"><p><strong>关于 Xenetic Biosciences</strong></p>
</div><p>Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.</p>
<div class="lb-trans"><p>Xenetic Biosciences, Inc.是一家专注于推进创新免疫肿瘤技术以应对难治性癌症的生物制药公司。公司的专有 DNase 技术旨在通过靶向中性粒细胞外陷阱（NETs）来改善现有治疗的效果，包括免疫疗法，这些 NETs 与癌症进展有关。Xenetic 目前专注于将其系统性 DNase 项目推进到临床，作为胰腺癌和局部晚期或转移性实体瘤的辅助治疗。</p>
</div><p>For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问公司网站 www.xeneticbio.com，并在 X、LinkedIn 和 Facebook 上与我们联系。</p>
</div><p><strong>FORWARD-LOOKING STATEMENTS</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as &#34;expects,&#34; &#34;plans,&#34; &#34;projects,&#34; &#34;will,&#34; &#34;may,&#34; &#34;anticipates,&#34; &#34;believes,&#34; &#34;should,&#34; &#34;intends,&#34; &#34;estimates,&#34; &#34;remain,&#34; &#34;focus&#34;, &#34;confidence in&#34;, &#34;potential&#34;, &#34;continues&#34;, &#34;warrants&#34;, and other words of similar meaning, including, but not limited to, all statements regarding our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，我们意图使其符合 1995 年《私人证券诉讼改革法》的安全港条款。本新闻稿中除历史事实陈述外的所有声明可能构成联邦证券法意义上的前瞻性声明。这些声明可以通过诸如 “预计”、“计划”、“项目”、“将”、“可能”、“预期”、“相信”、“应该”、“意图”、“估计”、“保持”、“关注”、“信心”、“潜力”、“持续”、“保证” 等词语以及其他类似含义的词语来识别，包括但不限于，所有关于我们专注于推进创新免疫肿瘤技术以应对难治性癌症的声明，DNase 平台通过靶向与癌症进展相关的中性粒细胞外陷阱（NETs）来改善现有治疗（包括免疫疗法）的结果，以及我们专注于将系统性 DNase 项目推进到临床作为胰腺癌和局部晚期或转移性实体瘤的辅助治疗的声明。此处包含的任何前瞻性声明均基于当前预期，并受到多种风险和不确定性的影响。许多因素可能导致我们的实际活动、表现、成就或结果与前瞻性声明中预期的活动和结果存在重大差异。可能导致实际活动、表现、成就或结果与此类计划、估计或预期存在重大差异的重要因素包括但不限于：（1）由于我们的制造和合作协议而产生的意外成本、费用或支出；（2）由于 DNase 平台的许可而产生的意外成本、费用或支出；（3）在 DNase 平台许可后，公司预期财务表现的不确定性；（4）未能实现 DNase 或 PolyXen 技术的预期潜力；（5）公司获得资金和实施其商业战略的能力；（6）董事会及其特别独立委员会进行的战略审查过程的结果和时机的不确定性，包括董事会在评估过程中可能决定不采取战略替代方案的可能性，公司因市场、监管和其他因素而无法完成审查所提出的任何战略替代方案的可能性，审查过程对我们业务造成的潜在干扰，以及评估过程的公告、暂停或完成及其结果对公司股价的潜在不利影响，以及与战略交易完成对公司当前业务运营、预期商业战略和产品开发计划的潜在影响相关的风险和不确定性；以及（7）其他风险因素，详见公司不时向 SEC 提交的报告，包括其 10-K 表格的年度报告、10-Q 表格的定期季度报告、8-K 表格的当前报告及其他向 SEC 提交的文件。上述重要因素的清单并不排他。此外，前瞻性声明也可能受到一般市场因素、一般经济和商业条件的负面影响，包括公共健康问题的潜在不利影响，以及地缘政治事件（如乌克兰和中东的冲突）对经济活动、竞争产品开发、产品可用性、联邦和州法规及立法、新产品候选和适应症的监管流程、可能出现的制造问题、专利状况、诉讼和股东行动主义等因素的影响。本文中包含的前瞻性声明仅在声明作出之日有效，公司不承担更新前瞻性声明的任何义务，法律要求的除外。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>Jenene Thomas</p>
<div class="lb-trans"><p>Jenene Thomas</p>
</div><p>(908) 824-0775</p>
<div class="lb-trans"><p>(908) 824-0775</p>
</div><p>xbio@jtcir.com</p>
<div class="lb-trans"><p>xbio@jtcir.com</p>
</div><p><strong>SOURCE:</strong> Xenetic Biosciences, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Xenetic Biosciences, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNjkxNg" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1116916"/></p>

Xenetic Biosciences, Inc. 宣布推迟 2025 年年度会议 | XBIO 股票新闻